WANTAI BIOLOGICAL(SH:603392) Xin Lang Cai Jing·2025-09-04 10:43Core Viewpoint - The company addresses investor concerns regarding the long-term efficacy and safety of its HPV vaccines, specifically the two-valent and nine-valent versions, emphasizing their compliance with regulatory standards and clinical trial results [1] Group 1: Vaccine Efficacy - The company's nine-valent HPV vaccine is an iterative product based on the same technology platform as the two-valent HPV vaccine, both of which underwent clinical trials to ensure safety and efficacy [1] - Long-term follow-up data from Phase III clinical trials indicate that the two-valent HPV vaccine can effectively prevent HPV 16/18 related high-grade precancerous lesions and persistent infections for at least ten years post-vaccination [1] - The company asserts that the two-valent HPV vaccine demonstrates excellent immune persistence over the long term [1] Group 2: Regulatory Compliance - The nine-valent HPV vaccine has passed rigorous evaluations and registration checks by the National Medical Products Administration [1] - The vaccine has also successfully undergone Good Manufacturing Practice (GMP) compliance inspections [1] Group 3: Competitive Landscape - The company acknowledges the existence of competing products in the market, such as those from Ruike and Kangle, but does not provide specific comparative data on their efficacy and safety [1]